Un vaccin folosit deja pe scară largă ar putea reduce riscul de infarct și AVC: „Efectul ar fi enorm”

A recent study indicates that the shingles vaccine, Shingrix, is linked to a 12% reduction in cardiovascular risk within three and a half years post-vaccination. This finding, based on medical records of 70,000 adults in the U.S., suggests that the vaccine's benefits may rival those of common antihypertensive medications. Researchers emphasize that if confirmed, this could significantly impact the prevention of coronary heart disease and strokes globally. The study also highlights the potential broader effects of the vaccine on the immune system, which may contribute to cardiovascular health. Further randomized trials are needed to validate these findings.